PER® New York Lung Cancer Symposium | Conference

Expert Discusses Next Steps With Immunotherapy in Lung Cancer

November 15th 2016

Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.

Using PD-L1 Expression to Determine Lung Cancer Treatments

November 15th 2016

Standard of care for newly diagnosed non-small cell lung cancer is shifting to include PD-L1 expression to determine the appropriate treatment plan, says Matthew D. Hellmann, MD.

Dr. Halmos on MET Mutations in Patients With NSCLC

November 15th 2016

Balazs Halmos, MD, director, Thoracic Oncology, director, Clinical Cancer Genomics, Montefiore Medical Center, discusses the prevalence of MET mutations in patients with non–small cell lung cancer (NSCLC).

Dr. West on Considering Factors for EGFR TKIs in NSCLC

November 15th 2016

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses factors he takes into consideration for EGFR tyrosine kinase inhibitors in patients who have EGFR-positive non–small cell lung cancer (NSCLC).

Emerging Data Could Rearrange Frontline EGFR TKIs in NSCLC

November 13th 2016

Individualizing frontline therapy for patients with non–small cell lung cancer based on preferences and clinical experience, as well as efficacy and safety data from pivotal trials, is an appropriate method for selecting EGFR-targeted agents.

Therapeutic Options Expanding for ALK-Rearranged NSCLC

November 13th 2016

The treatment landscape for patients with ALK-rearranged non–small cell lung cancer is changing rapidly, gearing up the potential for more therapeutic options to address the heterogeneity of the mechanism of resistance in this population.

Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLC

November 13th 2016

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).

Dr. Anne Chiang on Molecular Testing in Lung Cancer Treatment Planning

November 13th 2016

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

Explosion of Novel Agents, Liquid Biopsies Leading Advancements in Lung Cancer Field

November 12th 2016

Lung cancer treatment has undergone a game-changing transformation within the past few years, with a burst of FDA approvals of targeted agents and immunotherapies across a number of indications.

Dr. Oxnard on Delaying Second-Line Treatment in EGFR-Mutant Lung Cancer

November 9th 2015

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

PD-1 Agents Top Choice for Second-Line NSCLC

November 9th 2015

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Expert Examines Nuances of Switching Therapies in Progressive EGFR-Positive NSCLC

November 9th 2015

Patience is a virtue when it comes to deciding whether to switch therapies for individuals with metastatic non–small cell lung cancer who appear to be progressing on an EGFR-targeting regimen.

Upfront EGFR TKI Questions Remain in NSCLC

November 9th 2015

Multiple options currently exist for patients with EGFR-positive non–small cell lung cancer, with additional therapies on the horizon, making upfront treatment selection an increasingly difficult endeavor.

Dr. Levy on EGFR TKIs in Lung Cancer

November 9th 2015

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

Nivolumab Demonstrates Broad Efficacy in NSCLC

November 7th 2015

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Targeting Rare Mutations in NSCLC the Way of the Future

November 7th 2015

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

Checkpoint Inhibitors Show Promise in SCLC, Mesothelioma

November 7th 2015

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

Dr. Chandra Belani on Selecting Anti-PD-L1 Agents in Lung Cancer

November 7th 2015

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

Dr. Renato Martins on the Effects of Nivolumab and Ipilimumab

November 7th 2015

Dr. Renato G. Martins talks about the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti CTLA-4, in the treatment of lung cancer.

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

February 11th 2015

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.

NEXT PAGE
PREVIOUS PAGE